As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
The Role of GLP-1 Medications in Fatty Liver Disease Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy) and tirzepatide (Mounjaro), were originally developed to manage type 2 diabetes
Please try again This advertisement has not loaded yet, but your article continues below
GLP-1 medications are expensive often over $1,000 per month without insurance
She added: "Augustinus Bader Science was the only partner I trusted to bring this vision to life
It is important to keep in mind that people taking GLP-1 medications may already be at risk of developing SIBO for other reasons